Duopharm SA
1.2 FTEDuopharm reported total assets of €1.43m at the end of the 2024 financial year (annual accounts filed with the NBB on 02 Jan 2025), with 1.2 full-time equivalent.
The score of Duopharm shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2024
Change 2021 → 2024: Equity -16 % Total assets -17 % Headcount (avg FTE) -25 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Duopharm's annual accounts
Filed annual accounts
- Year ended 30 Jun 2024filed on 02 Jan 2025
- Year ended 30 Jun 2023filed on 29 Jan 2024
- Year ended 30 Jun 2022filed on 23 Dec 2022
- Year ended 30 Jun 2021filed on 31 Jan 2022
- Year ended 30 Jun 2020filed on 27 Jan 2021
Duopharm's financial analysis
- Solvency71.3%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Duopharm
Duopharm's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0417.916.679
- VAT number
- BE0417916679
- Peppol
- Registered · 0208:0417916679 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 15 Dec 1977
- Registered office
- 9280 Lebbeke
- Size
- Micro · 1.2 FTE
- Latest accounts
- 2024 · filed on 02 Jan 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Duopharm (SA) has been based in Lebbeke since 1977, active in: retail sale of pharmaceutical products. For 2024, it reports a net profit of 231,411 € and equity of €1.02m; its revenue is not published. With 1.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 71.3%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Duopharm
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Mees Sint-Truiden Retail sale of pharmaceutical products Sint-Truiden · balance sheet €1.43m
- Romarix Retail sale of pharmaceutical products Liedekerke · balance sheet €1.43m
- Pharmacie Jonckheere Retail sale of pharmaceutical products Tubize · balance sheet €1.43m
- Laleman Pharma Retail sale of pharmaceutical products Diksmuide · balance sheet €1.43m
- Dynamic Pharma Retail sale of pharmaceutical products Arlon · balance sheet €1.43m
- Sogipharma Retail sale of pharmaceutical products Wavre · balance sheet €1.43m
- Natessence Retail sale of pharmaceutical products Écaussinnes · balance sheet €1.43m
- Apoteek Piqueur Retail sale of pharmaceutical products Kapellen · balance sheet €1.42m
Frequently asked questions about Duopharm
What is the revenue of Duopharm?
Duopharm files its accounts in a format where revenue is optional: it is not published for 2024.
What is the VAT number of Duopharm?
In Belgium, the VAT number is the company number prefixed with BE: BE0417916679 for Duopharm, if the company is VAT-registered. Its company number (CBE) is 0417.916.679.
Where is the registered office of Duopharm?
According to the CBE register, the registered office of Duopharm is in 9280 Lebbeke.
What is the equity of Duopharm?
At the close of the 2024 financial year, the equity of Duopharm amounts to 1,018,350 €, a solvency of 71.3% of total assets.
How many people work at Duopharm?
1.2 full-time equivalents on average according to the 2024 social balance sheet.
Who manages Duopharm?
The register lists 3 active mandates at Duopharm. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Duopharm
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →